A phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) nano-immunoconjugate therapy for metastatic gynecological malignancies: MC1371 (NCT02020707) (1308)
Matthew S. Block(Mayo Clinic in Arizona), Svetomir N. Markovic(Mayo Clinic in Arizona), Carrie Strand(Mayo Clinic), Joel M. Reid(Children's Hospital of Philadelphia), Eleftheria Kalogera(Mayo Clinic), Andrea Wahner Hendrickson(Mayo Clinic in Arizona), Darragh O'Donoghue(Mayo Clinic in Arizona), Gretchen Glaser(WinnMed), Wendy K. Nevala(Mayo Clinic), Aminah Jatoi(Mayo Clinic in Arizona), Jill M. Schimke(Mayo Clinic), Amanika Kumar(Mayo Clinic in Florida), Megan E. Grudem(Mayo Clinic), Vera J. Suman(Mayo Clinic in Arizona), Carolyn M. Klampe(Mayo Clinic), Saravut J. Weroha(Mayo Clinic), Carrie Langstraat(Mayo Clinic in Arizona)
Cited by 1
Related Papers
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
|Journal of Clinical Oncology|2017|411
Adjuvant Radiotherapy and Chemotherapy for Pancreatic Carcinoma: The Mayo Clinic Experience (1975-2005)
|Journal of Clinical Oncology|2008|270
Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study
|Journal of Clinical Oncology|2008|210
Neurologic autoimmunity and immune checkpoint inhibitors
|Neurology|2020|158